INDUSTRY PROGRAMME2016.easd-industry.com/files/EASD16/EASD16_Ind... · FLASH GLUCOSE MONITORING:...

www.easd-industry.com

INTERPLANmedia & service gmbh

52nd Annual Meeting of the European Association for the Study of Diabetes

12 – 15 September 2016PROGRAMMEINDUSTRY

3

WELCOME ADDRESS

DEAR MEMBERS, DEAR GUESTS,

It is my great privilege to invite you to the 52nd EASD Annual Meeting which will take place from 12 to 16 September 2016.

The city of Munich will host the largest international scientifi c meeting on diabetes and its complications where the EASD will celebrate its 52nd Annual Meeting with an outstanding scientifi c programme.

Assembled under the chairmanship of our Honorary Secre-tary, Per-Henrik Groop, the programme will comprise six parallel tracks which will include stimulating symposia, keynote lectures and debates covering basic and clinical science.

The EASD Annual Meeting has a longstanding tradition of not only presenting science of the highest calibre, but also of bringing researchers and clinicians of the highest calibre together. This year will be no exception and will be even more accommodating thanks to our Virtual Meeting and active social networking.

I look forward to welcoming you in Munich, a city renowned for its history, music and culture, and take this opportunity to wish you an inspiring and stimulating EASD Annual Meeting of striving to promote excellence in diabetes care through research and education.

Juleen R. ZierathPresident EASD/EFSD

4

CONTENT

GENERAL INFORMATION 6

SCHEDULE 8

HALL OVERVIEW 10

PROGRAMME OF INDUSTRY SYMPOSIA Novo NordiskImproving care: individualised treatment across the diabetes spectrum 12

Sanofi Diabetes and CardiovascularFacing New Horizons: Optimism & Opportunities In Diabetes Management 14

AstraZenecaType 2 diabetes: Beyond the beta cell 16

PCM Scientific Transcending the template: strategies for optimising complex patient management 18

Merck Sharp & DohmeEvolving the Clinical Treatment Across a Broad Range of Patients With Type 2 Diabetes 19

Boehringer Ingelheim & Eli Lilly and Company Diabetes AllianceAddressing the challenges of kidney disease in type 2 diabetes 20

Eli Lilly & Boehringer IngelheimOvercoming insulin treatment challenges: what can we learn from clinical and real world evidences 21

Roche Diabetes Care Improving diabetes management with advances in health technology 22

AmgenReducing cardiovascular risk in diabetes: what does the future hold? 23

AbbottFLASH GLUCOSE MONITORING: Redefi ning Diabetes Management with Metrics beyond HbA1c 24

DexcomDexcom Continuous Glucose Monitoring: Leading the Way as the Standard of Care, Clinical Outcomes and Market Access 25

Takeda Pharmaceuticals InternationalCHANGING HEARTS & MINDS Delivering personalised medicine and support for post-ACS patients with T2D 26

5

CONTENT

PROGRAMME OF INDUSTRY EVENING SYMPOSIA Boehringer Ingelheim & Eli Lilly and Company Diabetes AllianceEvolving considerations in type 2 diabetes management: going beyond glucose control 27

Sanofi Diabetes and CardiovascularSynchronizing individual needs and treatment approaches: Time for a paradigm change in Type 2 diabetes? 28

Servier InternationalStrategies for achieving effective and sustained glycemic control Real world challenges for Type 2 Diabetes management 29

Novo NordiskThe pursuit of ultra-fast insulins 30

Sanofi and RegeneronHigh CV Risk Patients with Diabetes and Dyslipidaemia 31

Astra ZenecaWhat Science Can do in Diabetes 33

Novo NordiskChanging perceptions of obesity and its related comorbidities 34

Merck Sharp & DohmeClinical Treatment in Patients With Type 2 Diabetes: An Evolving Understanding for Clinicians 35

Sanofi Diabetes and CardiovascularThe missing evidence in diabetes management: Bridging The Gap Between Clinical Trials And Clinical Practice 36

PROGRAMME OF INDUSTRY MINI SYMPOSIA Merck KGaAPre-diabetes – What is it and what can be done against it? 32

Fukuda Denshi Co. LtdCAVI - Cardio-Ankle Vascular Index – A New Global Arterial Stiffness Index in Diabetic Patients 37

JDRF (sponsored by Novo Nordisk)T1D Performance in Excersise And Knowledge (PEAK) symposium 38

INDUSTRY EXHIBITION 39

IMPRINT 70

6

GENERAL INFORMATION

Due to safety reasons, the entrance to the conference site during the industry symposia on the occasion of the 52nd EASD Annual Meeting will be strictly controlled.

This means that each regular attendee of the symposia day has to be identifi ed as authorised by wearing a badge.

Our security staff will accept the following types of badges or name labels only:

• Regular delegate badge

• Regular exhibitor badge

• Special name tags, provided by the company itself, showing the status of the person wearing: “Invited by …, Guest of …, Technician of…“

Type of DelegateType of Badge

Access to the Scientifi c Sessions

13.– 16.09.16

Access to the Industry Exhibition

13.– 15.09.16

Access to Industry Symposia

12.09.16

Access to Industry Evening & Mini Symposia14. & 15.09.16

Speaker / Delegate registered for the Scientifi c Programme of the EASD Annual Meeting

Congress Badge ✔ ✔ ✔ ✔

Speaker / Delegateregistered as an exhibitor for the Industry Exhibition of the EASD Annual Meeting

Exhibitor Badge ✘ ✔ ✔ ✔

Company Speaker / Delegatenot registered for the EASD Annual Meeting

Own Company created Badge

✘ ✘ ✔ ✘


NoBadge ✘ ✘ ✘ ✘

Type of DelegateType of Badge

Access to the Scientifi c Sessions

13.– 16.09.16

Access to the Industry Exhibition

13.– 15.09.16

Access to Industry Symposia

12.09.16

Access to Industry Evening & Mini Symposia14. & 15.09.16

Speaker / Delegate registered for the Scientifi c Programme of the EASD Annual Meeting

Congress Badge ✔ ✔ ✔ ✔

Speaker / Delegateregistered as an exhibitor for the Industry Exhibition of the EASD Annual Meeting

Exhibitor Badge ✘ ✔ ✔ ✔


Own Company created Badge

✘ ✘ ✔ ✘


NoBadge ✘ ✘ ✘ ✘

7

GENERAL INFORMATION

Disclosure of Transfers of ValueEASD will publish the conditions and the scope of the support provided by FSA member companies to EASD on a voluntary basis. The publication will be carried out before and during the execution of the EASD Annual Meeting.

For the industry partners mentioned on the EASD Industry Website (http://www.easd-industry.com/industry.html > Dis-closure of Transfers of Value) we are informing regarding their overall support within the framework of the 52nd EASD Annual Meeting 2016.

8

ThannhauserHall

ThannhauserHall

MessestadtWest

ICM MunichFirst Floor

ICM MunichGround Floor

Main Entrance

MesseMunich

Exitonly

Messe Munich Ground FloorEhrlich

Hall

TiburtiusHall

KochHall

HeubnerHall

RubnerHall

Abstract Printing/Virtual

Meeting

Abstract Printing/

VirtualMeeting

Associations’Village

PressConference

Hall

PressCentre

Exhibition

LangerhansHall

MeyerhofHall

MinkowskiHall

AbstractPrinting

Poster

AbstractPrinting

Registration

Speakers’Lounge

BehringHall

HirschHall

VirchowHall

NaunynHall

KussmaulHall

BUS

HALL OVERVIEW ICM MESSE MUNICH

9

ThannhauserHall

ThannhauserHall

MessestadtWest

ICM MunichFirst Floor

ICM MunichGround Floor

Main Entrance

MesseMunich

Exitonly

Messe Munich Ground FloorEhrlich

Hall

TiburtiusHall

KochHall

HeubnerHall

RubnerHall

Abstract Printing/Virtual

Meeting

Abstract Printing/

VirtualMeeting

Associations’Village

PressConference

Hall

PressCentre

Exhibition

LangerhansHall

MeyerhofHall

MinkowskiHall

AbstractPrinting

Poster

AbstractPrinting

Registration

Speakers’Lounge

BehringHall

HirschHall

VirchowHall

NaunynHall

KussmaulHall

BUS

HALL OVERVIEW ICM MESSE MUNICH

10

SYMPOSIA ON THE OCCASION OF THE 52ND EASD ANNUAL MEETING

Monday, 12 September 2016

09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00Minkowski Hall Novo Nordisk

Page 12Meyerhof Hall Sanofi Diabetes and Cardiovascular

Page 14Langerhans Hall AstraZeneca

Page 16Thannhauser Hall

PCM Scientifi cPage 18

Naunyn Hall Merck Sharp & DohmePage 19

Kussmaul Hall Boehringer Ingelheim & Eli Lilly and Company Diabetes AlliancePage 20

Koch Hall Eli Lilly & Boehringer Ingelheim Page 21

Roche Diabetes CarePage 22

Heubner Hall AmgenPage 23

AbbottPage 24

Virchow Hall DexcomPage 25

Takeda Pharmaceuticals InternationalPage 26

Industry Symposia

Industry Evening Symposia

18:30 – 20:00Koch Hall AstraZeneca Page 33Heubner Hall Novo Nordisk Page 34Virchow Hall Merck Sharp & Dohme Page 35Hirsch Hall Sanofi Diabetes and Cardiovascular Page 36

Thursday, 15 September 2016

Industry Evening Symposia

18:45 – 20:15Naunyn Hall Boehringer Ingelheim & Eli Lilly and

Company Diabetes Alliance Page 27Kussmaul Hall Sanofi Diabetes and Cardiovascular Page 28Koch Hall Servier International Page 29Heubner Hall Novo Nordisk Page 30Virchow Hall Sanofi and Regeneron Page 31

Wednesday, 14 September 2016

11

SYMPOSIA ON THE OCCASION OF THE 52ND EASD ANNUAL MEETING

Monday, 12 September 2016

09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00Minkowski Hall Novo Nordisk

Page 12Meyerhof Hall Sanofi Diabetes and Cardiovascular

Page 14Langerhans Hall AstraZeneca

Page 16Thannhauser Hall

PCM Scientifi cPage 18

Naunyn Hall Merck Sharp & DohmePage 19

Kussmaul Hall Boehringer Ingelheim & Eli Lilly and Company Diabetes AlliancePage 20

Koch Hall Eli Lilly & Boehringer Ingelheim Page 21

Roche Diabetes CarePage 22

Heubner Hall AmgenPage 23

AbbottPage 24

Virchow Hall DexcomPage 25

Takeda Pharmaceuticals InternationalPage 26

Industry Mini Symposia

19:00 – 20:00Rubner Hall Fukuda Denshi Co. Ltd Page 37Behring Hall JDRF (sponsored by Novo Nordisk) Page 38


Industry Mini Symposia

19:00 – 20:00Rubner Hall Merck KGaA Page 32

Wednesday, 14 September 2016

12

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

IMPROVING CARE: INDIVIDUALISED TREATMENT ACROSS THE DIABETES SPECTRUM

Morning Session

MODERN INSULIN TREATMENT OF TYPE 1 DIABETESChair: Michael Nauck (Germany), Thomas Pieber (Austria)

09:00 – 09:10 Welcome Michael Nauck (Germany), Thomas Pieber (Austria)

09:10 – 09:25 The evolution of prandial insulin – approaching physiology Peter Kurtzhals (Denmark)

09:25 – 09:40 Translating faster onset into pharmacological performance Tim Heise (Germany)

09:40 – 09:55 From faster onset to clinical benefits in type 1 diabetes Chantal Mathieu (Belgium)

09:55 – 10:10 Hypoglycaemia in patients with type 1 diabetes treated with insulin degludec compared to insulin glargine U100: the double blinded SWITCH 1 trial Wendy Lane (USA), Simon Heller (UK)

10:10 – 10:30 Panel Discussion

10:30 – 11:00 Coffee

MANAGING OBESITY AND EARLY TYPE 2 DIABETES WITH GLP-1 RECEPTOR AGONISTS11:00 – 11:20 Can GLP-1 receptor agonists reduce the risk of T2DM? Carel le Roux (Ireland)

11:20 – 11:40 Switching from DPP-4 inhibitors to GLP- receptor agonists: what to expect? Richard Pratley (USA)

11:40 – 12:00 GLP-1 receptor agonists – are they all the same? Filip Knop (Denmark)


12:20 – 13:20 Lunch

MONDAY, 12 SEPTEMBER 2016 09:00 – 15:45Minkowski Hall

13

SYMPOSIA PROGRAMMEM

onday, 12 September 2016

MONDAY, 12 SEPTEMBER 2016 09:00 – 15:45Minkowski Hall

Afternoon Session

INTENSIFYING LATER-STAGE TYPE 2 DIABETES TREATMENTChair: Michael Nauck (Germany), Thomas Pieber (Austria)

13:20 – 13:30 Welcome Michael Nauck (Germany), Thomas Pieber (Austria)

13:30 – 13:45 Hypoglycaemia in patients with type 2 diabetes treated with insulin degludec compared to insulin glargine U100: the double blinded SWITCH 2 trial Wendy Lane (USA), Simon Heller (UK)

13:45 – 14:05 Improving glycaemic control with combined dual injectable therapy Melanie Davies (UK)

14:05 – 14:20 IDegLira: from clinical benefits to patient outcomes Stewart Harris (Canada)

14:20 – 14:35 From faster onset to clinical benefits in type 2 diabetes Athena Philis-Tsimikas (USA)


CARDIOVASCULAR OUTCOME TRIALS14:55 – 15:15 Results from the LEADER Trial John Buse (USA)

15:15 – 15:35 The impact of CVOTs on the management of type 2 diabetes Bernard Zinman (Canada)

15:35 – 15:45 Close Michael Nauck (Germany), Thomas Pieber (Austria)

Organised by: Novo Nordisk

14

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

Morning Session

BASAL INSULINS: CONFIDENCE TO NAVIGATE ACROSS THE METABOLIC CONTINUUM Chairs: J. Skyler (USA), E. Ferrannini (Italy)

09:00 – 09:15 The evolving face of diabetes J. Skyler (USA)

Managing risk in clinical practice: Considerations across the metabolic continuum09:15 – 09:35 Patient cases presentation C. Wysham (USA)

09:35 –10:10 The challenge of adherence: Can new insulins help? C. Wysham (USA), K. Khunti (UK)

10:10 – 10:30 Hypoglycaemia in context R. Ritzel (Germany)

10:30 – 10:50 The journey to control in special populations J. Escalada (Spain)

10:50 – 11:10 Addressing dyslipidaemia in patients with diabetes and high cardiovascular risk K. Ray (UK)

11:10 – 11:30 Real-world contributions to the understanding of disease management in T2DM N. Freemantle (UK)

11:30 – 11:50 Panel discussion: Key considerations for clinical practice across the metabolic continuum J. Skyler (USA), C. Wysham (USA), K. Ray (UK)

11:50 – 12:00 Audience questions 12:00 – 13:00 Lunch

FACING NEW HORIZONS: OPTIMISM & OPPORTUNITIES IN DIABETES MANAGEMENT

MONDAY, 12 SEPTEMBER 2016 09:00 – 16:00Meyerhof Hall

15

SYMPOSIA PROGRAMMEM


Afternoon Session

TITRATABLE CO-FORMULATIONS: CHANGING THE PATH TO GLYCAEMIC CONTROLChairs: J. Skyler (USA), E. Ferrannini (Italy)

13:00 – 13:10 Welcome back, introduction and overview of the afternoon session E. Ferrannini (Italy)

Changing the path to glycaemic control in T2DM13:10 – 13:30 New paths to glycaemic control A. Cheng (Canada)

The emerging role of titratable co-formulations: the LixiLan programme results13:30 – 13:50 – in patients failing on OADs J. Rosenstock (USA)

13:50 – 14:10 – in patients uncontrolled on basal insulin V. Aroda (USA)

14:10 – 14:45 Debate: Sequential vs simultaneous treatment approaches – A new management paradigm J. Rosenstock (USA), N. Skolnik (USA)

The road ahead14:45 – 15:05 How are CVOTs changing the road to control? J. Probstfi eld (USA)

15:05 –15:25 The next treatment options for the journey ahead C. Bailey (UK)

15:25 – 15:50 How close are we to revolutionising diabetes management? W. Cefalu (USA)

15:50 – 16:00 Meeting summary and close E. Ferrannini (Italy)

Organised by: Sanofi Diabetes and Cardiovascular

FACING NEW HORIZONS: OPTIMISM & OPPORTUNITIES IN DIABETES MANAGEMENT

MONDAY, 12 SEPTEMBER 2016 09:00 – 16:00Meyerhof Hall

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

TYPE 2 DIABETES: BEYOND THE BETA CELL

MONDAY, 12 SEPTEMBER 2016 09:30 – 16:15Langerhans Hall

Morning Session

Chairs: Baptist Gallwitz (Germany), Jiten Vora (UK/AstraZeneca)

09:30 – 10:00 Delegate journey/coffee

SESSION 1: GLYCAEMIC CONTROL: IS IT TIME TO MOVE ON?10:00 – 10:15 Should glycaemic control be central to the management of Type 2 diabetes? Tina Vilsbøll (Denmark)

10:15 – 10:25 Chairs’ welcome and introduction Baptist Gallwitz (Germany), Jiten Vora (UK/AstraZeneca)

SESSION 2: CARDIOMETABOLIC MECHANISMS UNDERLYING TYPE 2 DIABETES: THE NEXT THERAPEUTIC TARGET10:25 – 10:45 Can we reduce the incidence of macrovascular complications? Neil Poulter (UK)

10:45 – 11:05 Cardiovascular outcome trials: Current status Bernard Zinman (Canada)

11:05 – 11:25 Cardiovascular outcome trials: Implications for clinical practice Juris Meier (Germany)

11:25 – 11:35 Discussion

11:35 – 11:55 Is there more to learn about renal impairment in Type 2 diabetes? Mark Cooper (Australia)

11:55 – 12:15 Preserving renal function beyond glycaemic control – myth or reality? David Cherney (Canada)


12:25 – 12:45 Hormonal dysregulation: What is the impact on glycaemic control and the broader pathophysiology? Daniel Drucker (Canada)

12:45 – 13:05 Does management of the broader pathophysiology improve outcomes in Type 2 diabetes? Jens Holst (Denmark)


13:15 – 14:15 Lunch break

12:25 – 12:45 Hormonal dysregulation: What is the impact on glycaemic control and the

12:45 – 13:05 Does management of the broader

16

SYMPOSIA PROGRAMMEM


MONDAY, 12 SEPTEMBER 2016 09:30 – 16:15Langerhans Hall

TYPE 2 DIABETES: BEYOND THE BETA CELL

Afternoon Session

Chairs: Baptist Gallwitz (Germany), Jiten Vora (UK/AstraZeneca)

SESSION 3: INDIVIDUALISED MANAGEMENT OF TYPE 2 DIABETES: THE PATIENT-CENTRED APPROACH14:15 – 14:20 Chairs’ introduction Baptist Gallwitz (Germany), Jiten Vora (UK/AstraZeneca)

14:20 – 15:05 Is it time to shift the focus away from glycaemic control? Juris Meier (Germany), Chantal Mathieu (Belgium)

15:05 – 15:25 Combination therapy in Type 2 diabetes – why, what and when? Chantal Mathieu (Belgium)

15:25 – 15:50 Panel discussion: Where do novel therapies best fit within the treatment paradigm? Panel: Jens Holst (Denmark), Juris Meier (Germany), Chantal Mathieu (Belgium), Daniel Drucker (Canada)

SESSION 4: TREATING TODAY, MANAGING FOR THE FUTURE15:50 – 16:05 From the science of today to the medicines of tomorrow Marcus Schindler (Sweden/AstraZeneca)

16:05 – 16:15 Type 2 diabetes: Managing our patients beyond the beta cell Panel: Jens Holst (Denmark), Juris Meier (Germany), Chantal Mathieu (Belgium), Daniel Drucker (Canada), Marcus Schindler (Sweden/AstraZeneca) (Sweden/

17

Organised by: AstraZeneca

18

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

TRANSCENDING THE TEMPLATE: STRATEGIES FOR OPTIMISING COMPLEX

PATIENT MANAGEMENT

MONDAY, 12 SEPTEMBER 2016 13:30 – 16:00Thannhauser Hall

Afternoon Session

Co-Chairs: Prof Silvio Inzucchi (USA), Prof David Matthews (UK)

13:30 – 13:40 Chairs’ welcome Prof David Matthews (UK)

13:40 – 13:55 Setting targets and optimizing strategies in complex patients Prof Silvio Inzucchi (USA)

13:55 – 14:25 Interactive patient case study: heart failure and coronary artery disease Dr Mikhail Kosiborod (USA)

14:25 – 14:55 Interactive patient case study: severe obesity Prof Rachel Batterham (UK)

14:55 – 15:45 Interactive patient case study: advanced microvascular disease Prof Roland Schmieder (Germany) Prof Dr Hans-Peter Hammes (Germany)

15:45 – 16:00 Chairs’ summary Prof David Matthews (UK)

Organised by: PCM Scientific and supported by an independent educational grant from Novartis Pharma AG (CME accredited)

19

SYMPOSIA PROGRAMMEM


Organised by: Merck Shark & Dohme

EVOLVING THE CLINICAL TREATMENT ACROSS A BROAD RANGE OF PATIENTS WITH TYPE 2

DIABETES

MONDAY, 12 SEPTEMBER 2016 14:30 – 17:00 Naunyn Hall

Afternoon Session

Co-Chairs: Steven Kahn (USA), Harald Sourij (Austria)

14:30 – 14:35 Welcome and Opening Remarks Steven Kahn (USA), Harald Sourij (Austria)

14:35 – 14:55 Pathophysiology of the Beta Cell: Addressing It With DPP-4 Inhibition Steven Kahn (USA)

14:55 – 15:00 Q&A

15:00 – 15:20 Clinical Roundtable: DPP-4 Inhibitors and Metformin: The Endocrine Basis for Their Use in Combination Faculty

15:20 – 15:25 Q&A

15:25 – 15:45 Newly Emerging Data From the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) Cardiovascular Safety Trial: A Principal Investigator’s Perspective Harald Sourij (Austria)

15:45 – 15:50 Q&A

15:50 – 16:10 What Is the Evidence for Primary and Secondary Prevention of Cardiovascular Events in Patients With T2DM? Anselm Gitt (Germany)

16:10 – 16:15 Q&A

16:15 – 16:35 What About the Hospitalized Patient With Hyperglycemia? Mariana Monteiro (Portugal)

16:35 – 16:40 Q&A

16:40 – 16:55 Clinical Considerations: Evolving the Spectrum of Patient Care in Type 2 Diabetes Faculty16:55 – 17:00 Final Comments and Summary Steven Kahn (USA), Harald Sourij (Austria)

20

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

ADDRESSING THE CHALLENGES OF KIDNEY DISEASE IN TYPE 2 DIABETES

MONDAY, 12 SEPTEMBER 2016 14:30 – 16:30Kussmaul Hall

Afternoon Session

Moderator: Alice Cheng (Canada), Johannes Mann (Germany)

14:30 – 14:35 Welcome and introduction Alice Cheng (Canada)

14:35 – 14:55 Current challenges of managing kidney disease in type 2 diabetes: could we do more? Johannes Mann (Germany)

14:55 – 15:45 Glucose control and beyond: potential renal effects of DPP-4 and SGLT2 inhibition Mark Cooper (Australia), Alice Cheng (Canada)

15:45 – 16:05 Future perspectives and implications Andrew Frankel (UK)

16:05 – 16:25 Panel discussion: The role of kidney disease in type 2 diabetes management All faculty moderated by Johannes Mann (Germany)

16:25 – 16:30 Closing remarks Alice Cheng (Canada)

Organised by: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

21

SYMPOSIA PROGRAMMEM


OVERCOMING INSULIN TREATMENT CHALLENGES: WHAT CAN WE LEARN FROM CLINICAL AND

REAL WORLD EVIDENCES

MONDAY, 12 SEPTEMBER 2016 11:00 – 12:30Koch Hall

Morning Session

11:00 – 11:15 Introduction to the reality of people treated with insulin Melanie Davies (UK)

11:15 – 12:00 Insulin treatment regimens in T2DM: how does real world evidence support RCT findings? Dennis Raccah (France), Seoyoung Kim (USA)

12:00 – 12:30 Expert perspectives: learnings and options to overcome insulin treatment challenges Bill Polonsky (USA), Melanie Davies (UK), Peter Lin (Canada)

12:30 Summary and Close Melanie Davies (UK)

Organised by: Eli Lilly & Boehringer Ingelheim

22

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

IMPROVING DIABETES MANAGEMENT WITH ADVANCES IN HEALTH TECHNOLOGY

MONDAY, 12 SEPTEMBER 2016 14:30 – 17:00Koch Hall

Afternoon Session

Chairs: Gnanagurudasan Prakasam (USA), Rolf Hinzmann (Germany)

14:30 – 14:40 Introduction

14:40 – 15:05 Improving treatment satisfaction with the Accu-Chek® Connect diabetes management system Pablo Mora (USA)

15:05 – 15:30 The next generation Accu-Chek® diabetes management system Nigel Surridge (USA)

15:30 – 15:55 How modern technologies enable integrated diabetes management Matthias Axel Schweitzer (Germany)

15:55 – 16:20 Do insulin pumps dose insulin correctly? Ralph Ziegler (Germany)

16:20 – 16:45 Characteristics of the new Accu-Chek®

Insight CGM system Günther Schmelzeisen-Redeker (Germany)

16:45 – 17:00 Discussion and closing

Organised by: Roche Diabetes Care

23

SYMPOSIA PROGRAMMEM


Organised by: Amgen

REDUCING CARDIOVASCULAR RISK IN DIABETES: WHAT DOES THE FUTURE HOLD?

MONDAY, 12 SEPTEMBER 2016 10:00 – 12:30Heubner Hall

Morning Session

10:00 – 10:10 Welcome and introduction Naveed Sattar (UK)

10:10 – 10:30 Cardiovascular risk in patients with diabetes Diethelm Tschöpe (Germany)

10:30 – 10:50 Diabetes, lipids and CVD risk Jan Borén (Sweden)

10:50 – 11:10 Reducing LDL by PCSK9 inhibition: evidence of efficacy and safety in patients with diabetes Naveed Sattar (UK)

11:10 – 11:30 PCSK9 inhibition: an opportunity for CV risk reduction? Terje Pedersen (Norway)

11:30 – 11:55 Patient vignette Panel

11:55 – 12:25 Panel discussion and Q&A Terje Pedersen (Norway)

12:25 – 12:30 Concluding remarks Terje Pedersen (Norway)

24

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

Organised by: Abbott

FLASH GLUCOSE MONITORING: REDEFINING DIABETES MANAGEMENT WITH METRICS

BEYOND HBA1C

MONDAY, 12 SEPTEMBER 2016 14:30 – 17:00Heubner Hall

Afternoon Session

Chair: Thomas Haak (Germany)

14:30 – 14:40 Introduction and opening Thomas Haak (Germany)

14:40 – 15:00 Flash Glucose Monitoring in the pediatric population Thomas Danne (Germany)

15:00 – 15:25 Hypoglycemia in type 2 diabetes: myths, facts and future directions Ramzi Ajjan (UK)

15:25 – 15:50 Is Time in Range the better HbA1c? Michael Joubert (France)

15:50 –16:20 IMPACT: Data from a recent Flash Glucose Monitoring clinical outcome trial in type 1 diabetes Jan Bolinder (Sweden)

16:20 – 16:45 Concluding thoughts: the limitations of HbA1c Irl B. Hirsch (USA)

16:45 – 17:00 Q&A session

25

SYMPOSIA PROGRAMMEM


DEXCOM CONTINUOUS GLUCOSE MONITORING: LEADING THE WAY AS THE STANDARD OF CARE,

CLINICAL OUTCOMES AND MARKET ACCESS

MONDAY, 12 SEPTEMBER 2016 10:00 – 12:30Virchow Hall

Morning Session

10:00 – 10:50 CGM vs. FGM – Results of a Head to Head Study with the Dexcom G5® Mobile and the Abbott Freestyle® Libre Nick Oliver (UK)

10:50 – 11:40 CGM and Multiple Daily Injection Patients: A1c Outcomes and Clinical Benefit Demonstrated by the COMISAIR Study Martin Prazny (Czech Republic)

11:40 – 12:30 CGM Reimbursement Update & Cost Effectiveness in 2016 Claudia Graham (USA)

Organised by: Dexcom

26

SYMPOSIA PROGRAMME

Monday, 12 Septem

ber 2016

CHANGING HEARTS & MINDS DELIVERING PERSONALISED MEDICINE AND

SUPPORT FOR POST-ACS PATIENTS WITH T2D

MONDAY, 12 SEPTEMBER 2016 14:30 – 17:00Virchow Hall

Afternoon Session

Chair: Prof. Antonio Ceriello (Italy)

14:30 – 14:40 Welcome and introduction Prof. Antonio Ceriello (Italy)

14:40 – 15:10 High-risk patient profiles – how biomarkers can facilitate treatment individualisation Prof. George Bakris (USA)

15:10 – 15:40 How physicians can use clinical decision- making tools to help individualise treatment Prof. Antonio Ceriello (Italy)

15:40 – 16:20 Digital tools to help physicians support patient self-management Dr Stefano Bonacina (Sweden)

16:20 – 16:55 Panel discussion: a multidisciplinary framework for continuity of care Prof. Antonio Ceriello (Italy) Prof. George Bakris (USA) Dr Stefano Bonacina (Sweden) Dr Francesc Xavier Cos (Spain)

16:55 – 17:00 Conclusion and symposium close Prof. Antonio Ceriello (Italy)

Organised by: Takeda Pharmaceuticals International, Inc.

Wednesday, 14 Septem

ber 2016

27

SYMPOSIA PROGRAMME

EVOLVING CONSIDERATIONS IN TYPE 2 DIABETES MANAGEMENT: GOING BEYOND GLUCOSE CONTROL

WEDNESDAY, 14 SEPTEMBER 2016 18:45 – 20:15Naunyn Hall

Evening Session

Moderator: Christoph Wanner (Germany), Alice Cheng (Canada)

18:45 – 18:50 Welcome and introduction Christoph Wanner (Germany)

18:50 – 19:10 Are we doing enough for patients with type 2 diabetes? George Bakris (USA)

19:10 – 19:30 Addressing clinical outcomes in type 2 diabetes beyond standard of care: learnings from EMPA REG OUTCOME® Christoph Wanner (Germany)

19:30 – 19:50 Novel strategies to slow the progression of kidney disease in type 2 diabetes: an emerging mechanism of SGLT2 inhibition David Cherney (USA)

19:50 – 20:10 Panel discussion: Reassessing current and future treatment approaches in type 2 diabetes All faculty

20:10 – 20:15 Closing remarks Alice Cheng (Canada)

20:15 Meeting close

Organised by: Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

28

SYMPOSIA PROGRAMME


ber 2016


SYNCHRONIZING TREATMENT APPROACHES TO NEEDS: TIME FOR A PARADIGM CHANGE IN

TYPE 2 DIABETES

WEDNESDAY, 14 SEPTEMBER 2016 18:45 – 20:15Kussmaul Hall

Evening Session

Chair: L. Meneghini (USA)

18:45 – 18:55 Welcome and introduction L. Meneghini (USA)

18:55 – 19:15 A new view on a persistent conundrum: Combatting delays in intensifying treatment R. McCrimmon (UK) Moderator: J. Anderson (USA)

19:15 – 19:35 Options to simultaneously address pathophysiology and inertia A. Philis-Tsimikas (USA)

19:35 – 19:45 Future blast: Innovations in drug delivery devices S. Edelman (USA)

19:45 – 20:05 Changing treatment paradigms with fixed-ratio combination therapies J. Vidal (Spain) Moderator: J. Anderson (USA)

20:05 – 20:13 Audience and panel discussion: Individualizing care through titratable fixed-ratio combination treatment approaches All

20:13 – 20:15 Closing remarks L. Meneghini (USA)

Sanofi Diabetes and Cardiovascular

29

SYMPOSIA PROGRAMMEW

ednesday, 14 September 2016

STRATEGIES FOR ACHIEVING EFFECTIVE AND SUSTAINED GLYCEMIC CONTROL

REAL WORLD CHALLENGES FOR TYPE 2 DIABETES MANAGEMENT

WEDNESDAY, 14 SEPTEMBER 2016 18:45 – 20:15Koch Hall

Evening Session

Chairs: Luc Van Gaal (Belgium), Robert R. Henry (USA)

18:45 – 18:50 Introduction Luc Van Gaal (Belgium)

18:50 – 19:10 Should glycemic control still be at the core of T2D management? Pierre Gourdy (France)

19:10 – 19:30 When treatment goals are not met: the difficulty in translating to the real-world setting Luc Van Gaal (Belgium)

19:30 – 19:50 Perspectives and new options for effective and sustained control Juris Meier (Germany)

19:50 – 20:10 Panel discussion

20:10 – 20:15 Conclusion Robert R. Henry (USA)

Organised by: Servier International

30

SYMPOSIA PROGRAMME


ber 2016

THE PURSUIT OF ULTRA-FAST INSULINS

WEDNESDAY, 14 SEPTEMBER 2016 18:45 – 20:15Heubner Hall

Evening Session

Chair: Lena Landstedt-Hallin (Sweden)

18:45 – 18:50 Welcome and introduction Lena Landstedt-Hallin (Sweden)

18.50 – 19:10 Pharmacological properties of ultra-fast insulins Tim Heise (Germany)

19:10 – 19:35 Review of the onset programme results Keith Bowering (Canada)

19:35 – 20:00 Perspectives for pump use David Kerr( UK)

20:00 – 20:15 Panel discussion All faculty


31

SYMPOSIA PROGRAMMEW

ednesday, 14 September 2016

HIGH CV RISK PATIENTS WITH DIABETES AND DYSLIPIDAEMIA

WEDNESDAY, 14 SEPTEMBER 2016 18:45 – 20:15Virchow Hall

Evening Session

Chair: Klaus Parhofer (Germany)

18:45 – 18:50 Introduction Klaus Parhofer (Germany)

18:50 – 19:20 Lipid targets in patients with diabetes: debate – LDL-C should be the primary target Ulrich Laufs (Germany)

– Non-HDL-C should be the primary target Alberto Zambon (Italy)

19:20 – 19:50 Which patients with diabetes will benefit the most from additional lipid lowering therapy? Lawrence Leiter (Canada)

19:50 – 20:10 Challenges in the management of diabetes: how do we implement new evidence when managing cardiovascular risk in patients with diabetes? George Grunberger (USA)

20:10 – 20:15 Conclusion Klaus Parhofer (Germany)

Organised by: Sanofi and Regeneron

32

SYMPOSIA PROGRAMME


ber 2016

PRE-DIABETES – WHAT IS IT AND WHAT CAN BE DONE AGAINST IT?

WEDNESDAY, 14 SEPTEMBER 2016 19:00 – 20:00Rubner Hall

Evening Session

19:00 – 19:15 What is “pre-diabetes” Rury Holman (UK)

– Is it a “disease”? – Prevalence now and in the future

19:15 – 19:30 RCT findings for diet & exercise in pre-diabetes: What diet & exercise programme should be recommended? Jaakko Tuomilehto (Finland)

19:30 – 19:45 RCT findings for pharmacological inter- ventions: How should we prevent/treat “pre-diabetes”? Rury Holman (UK)

19:45 – 20:00 Interactive discussion All

Organised by: Merck KGaA


33

SYMPOSIA PROGRAMME

Organised by: AstraZeneca

WHAT SCIENCE CAN DO IN DIABETES

THURSDAY, 15 SEPTEMBER 2016 18:30 – 20:00Koch Hall

Evening Session

Chair: Jiten Vora (UK/AstraZeneca)

18:30 – 19:00 Reception

19:00 – 19:05 Welcome Jiten Vora (UK/AstraZeneca)

What Science can Do Bruce Cooper (UK/AstraZeneca)

Current and forthcoming opportunities for diabetes treatment

19:05 – 19:15 Role of monotherapies today Clifford Bailey (UK)

19:15 – 19:25 Opportunities from combination treatments Francesco Giorgino (Italy)

19:25 – 19:35 What does the future look like in diabetes management Melanie Davies (UK)

19:35 Panel Discussion

19:50 – 20:00 AstraZeneca R&D highlights William Haynes (Sweden/AstraZeneca)

20:00 Close

34

SYMPOSIA PROGRAMME



CHANGING PERCEPTIONS OF OBESITY AND ITS RELATED COMORBIDITIES

THURSDAY, 15 SEPTEMBER 2016 18:30 – 20:00Heubner Hall

Evening Session

Chair: Matthias Blüher (Germany)

18:30 – 18:40 Welcome and introduction Matthias Blüher (Germany)

18:40 – 19:00 Uncovering the risks associated with obesity Leigh Perreault (USA)

19:00 – 19:20 Management of obesity: what options do we have? John Wilding (UK)

19:20 – 19:40 From clinical trials to clinical practice David Lau (Canada)

19:40 – 19:55 Panel discussion All faculty

19:55 – 20:00 Summary and closure Matthias Blüher (Germany)

35

SYMPOSIA PROGRAMMEThursday, 15 Septem

ber 2016

Organised by: Merck Sharp & Dohme

CLINICAL TREATMENT IN PATIENTS WITH TYPE 2 DIABETES: AN EVOLVING UNDERSTANDING

FOR CLINICIANS

THURSDAY, 15 SEPTEMBER 2016 18:30 – 20:00Virchow Hall

Evening Session

Chair: Michael Nauck (Germany)

18:30 – 18:35 Welcome and Opening Remarks Michael Nauck (Germany)

18:35 – 18:50 The Case for Early Multiple Combination Therapy of Type 2 Diabetes: The Role of DPP-4 Inhibitors Bernard Zinman (Germany)

18:50 – 18:55 Q&A 18:55 – 19:10 Across a Broad Spectrum of Type 2 Diabetes Patients: Efficacy and Safety of DPP-4 Inhibitors in Older Type 2 Diabetic Patients With Multiple Comorbidities Lawrence Leiter (Canada)

19:10 – 19:15 Q&A

19:15 – 19:30 Newly Emerging Data From the TECOS (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) Cardiovascular Safety Trial: A Cardiologist’s View Nikolaus Marx (Germany)

19:30 – 19:35 Q&A

19:35 – 19:55 Clinical Considerations: Evolving the Spectrum of Patient Care in Type 2 Diabetes Faculty

19:55 – 20:00 Final Comments and Summary Michael Nauck (Germany)

36

SYMPOSIA PROGRAMME



THE MISSING EVIDENCE IN DIABETES MANAGEMENT: BRIDGING THE GAP BETWEEN

CLINICAL TRIALS AND CLINICAL PRACTICE

THURSDAY, 15 SEPTEMBER 2016 18:30 – 20:00 Hirsch Hall

Evening Session

Chair: C. Wysham (USA)Moderator: N. Freemantle (UK)

18:30 – 18:45 Welcome, Introduction And Overview C. Wysham (USA)

18:45 – 19:10 What Can we Learn About Diabetes from Different Sources of Data H. Gerstein (Canada)

19:10 – 19:20 Future Blast: Big Data, Big Change D. Kerr (USA)

19:20 – 19:55 Revealing The Missing Evidence: Real-life Studies with Basal Insulin Therapy T. Bailey (USA)

19:55 – 20:00 Summing Up: Closing Remarks C. Wysham (USA)

37

SYMPOSIA PROGRAMMEThursday, 15 Septem

ber 2016

CAVI – CARDIO-ANKLE VASCULAR INDEX – A NEW GLOBAL ARTERIAL STIFFNESS INDEX

IN DIABETIC PATIENTS

THURSDAY, 15 SEPTEMBER 2016 19:00 – 20:00Rubner Hall

Evening Session

Chairs: Prof. Roland Asmar (Switzerland), Prof. Paul Valensi (France)

19:00 – 19:20 CAVI, Guiding Treatment for Arterial Dysfunction, Independent of Blood Pressure? The Vasera Trial in People with and at Risk of Type 2 Diabetes Prof. Kennedy Cruickshank (UK)

19:20 – 19:40 The Impact of Arterial Stiffness in Diabetic Management Prof. Kohji Shirai (Japan)

19:40 – 20:00 Metabolic Risk Factors and CAVI – The Triple A Multicentre Study Prof. Roland Asmar (Switzerland)

Organised by: Fukuda Denshi Co. Ltd

38

SYMPOSIA PROGRAMME


T1D PERFORMANCE IN EXERCISE AND KNOWLEDGE (PEAK) SYMPOSIUM

THURSDAY, 15 SEPTEMBER 2016 19:00 – 20:00Behring Hall

Evening Session

19:00 –19:10 An Introduction to JDRF PEAK Aaron Kowalski (USA)

19:10 –19:40 The PEAK Healthcare Professional Curriculum in a Nutshell Peter Adolfsson (Sweden) Francesca Annan (UK) Rory J. McCrimmon (UK)

19:40 –19:50 Bringing PEAK to the Patient Peter Adolfsson (Sweden)

19:50 –20:00 What’s Next All

Organised by: JDRF (sponsored by Novo Nordisk)

Industry Exhibition

39

40

Industry Exhibition

EXHIBITION PLAN

Lunch Snacks/CoffeePoint

Lunch Snacks/CoffeePoint

Lunch Snacks/

CoffeePoint

ExhibitorService

V.01

R.02

R.03 R.01 S.01 S.09

S.07

S.05

S.06

S.01A

S.02

S.04

U.05U.04 U.02 U.01

P.03P.02

Q.01Q.02Q.03Q.04Q.05Q.06

Q.09

Q.07

P.01

G.01G.02

G.03G.04

G.05

G.06G.07

F.06F.05

F.04F.03

F.01E.04

E.02

E.03 E.01

A.01A.02 A.03 A.04

B.04B.02B.02A

B.01

D.11D.01

D.02

J.01

J.02

J.10

J.04

J.03

J.06

D.04 D.03

H.01

H.02

N.01 M.01L.01

L.02L.03L.04M.08M.07

M.06

M.04M.02N.02N.03

M.03L.05L.06L.07

K.05

K.03

P.04

P.05

V.02 V.03

Entrance/to Hall B.0,

Lecture Halls,Congress Center,

Registration

Entrance/to Lecture Halls B.02

Entrance/to Lecture Halls B.02

EntranceEntrance

EntranceEntrance

to Plenary Hall C.01to Poster Hall C.02

41

Industry ExhibitionLIST OF EXHIBITORS

Company BoothA.MENARINI DIAGNOSTICS S.04Abbott Diabetes Care Inc. M.02ACON LABORATORIES,INC. B.04Adelphi Real World L.06Alere International Ltd M.07Allpresan – neubourg skin care V.03ARKRAY Europe B.V. D.11ARTSANA S.P.A. – PIC SOLUTION L.01Ascensia Diabetes Care N.03AstraZeneca N.01Becton Dickinson France S.A.S. E.03bio.logis Center for Human Genetics L.05Boehringer Ingelheim E.02Cadila Healthcare Ltd. S.01Cardiff University L.03Cellnovo Group A.02ClinTriCare GmbH & Co. KG G.01CODHy Q.05Crown Bioscience B.01Danish Diabetes Academy Q.04Dexcom, Inc. S.06Diagnoptics Technologies B.V. U.05Diamesco Co., Ltd. S.02Diasend AB B.03Edge Consulting srl B.02EFPIA F.04Eli Lilly and Company D.02Elsevier BV Q.06Emperra GmbH L.02EOFLOW Co., Ltd. Q.02Eyenuk Inc. B.02AForaCare Suisse AG M.03Fukuda Denshi Co. Ltd P.01gbo Medizintechnik AG Q.01GI Dynamics M.08GlaxoSmithKline G.03Glenmark Pharmaceuticals Ltd. S.01AHRA Healthcare Research & Analytics Q.03IBL International GmbH F.05IDx Europe B.V. V.02iHealth Europe J.06IME-DC GmbH J.10Impeto Medical A.01Infopia Co., Ltd. D.03Inside Biometrics Ltd F.06Intarcia Therapeutics, Inc. R.03

Company BoothIntegrity Applications J.04INVITALIS GmbH Q.07i-SENS, Inc. E.04Janssen R.01Johnson & Johnson Family of Diabetes Care Companies R.01Karger Publishers G.02LUPIN LTD U.02MED TRUST Handelsges.m.b.H. P.04MEDEXEL CO., LTD A.03Medical Supply Co., Ltd. L.04Medscape Diabetes & Endocrinology S.05Medtronic International Trading Sàrl E.01MEDTRUM TECHNOLOGIES INC. A.04Mitsubishi Rayon Cleansui Co Ltd K.04MSD J.02Mylan S.09Novartis Pharma AG H.01novel gmbh G.07Novo Nordisk A/S H.02Novo Nordisk A/S J.03Optomed Oy P.02Phoenix Europe GmbH Q.09POCTech Medical M.04PODARTIS SRL G.07REGENERON D.04Research Diets, Inc. U.01Roche Diabetes Care GmbH J.01SANOFI D.04/M.01SERVIER R.02Shenzhen Lifotronic Technology Co.,Ltd K.03SOOIL Development Co., Ltd. M.06Steno Diabetes Center U.04Takeda Pharmaceuticals International AG D.01The JAMA Network P.03Time Research Limited G.04Trividia Health, Inc. S.07VibroSense Dynamics AB F.03ViCentra BV V.01VPD BLED d.o.o. G.05Welch Allyn K.05Wiley G.06Wisepress Medical Bookshop P.05Wuxi Apex Medical Co., Ltd. L.07Ypsomed AG N.02

42

EXHIBITOR PROFILES

Industry Exhibition

A.MENARINI DIAGNOSTICS S.04City, Country: Florence, Italy Email: [email protected] Website: www.menarinidiagnostics.com

A. Menarini Diagnostics, the Human Touch of Technology: more than 35 years dedicated to helping healthcare professionals make safe and sustainable diagnoses, meeting and exceeding the technological needs of Europe’s most prominent healthcare professionals, improving and enhancing the quality of life of people with diabetes all over the world and promptly and effi -ciently satisfying today’s diagnostics needs whilst maintaining diagnostics management both safe and cost effective.

Abbott Diabetes Care Inc. M.02City, Country: Alameda, United States of America Email: [email protected] Website: www.abbottdiabetescare.co.uk

At Abbott, we believe people with diabetes should have the free-dom to enjoy vigorous, active lives. That’s why we’re focused on helping people with diabetes manage their health more effectively and comfortably. We develop safe, accurate, and easy-to-use products that provide our consumers and their healthcare teams with the data they need for more informed treatment decisions. We’re revolutionizing the way people monitor their glucose with the FreeStyle Libre Flash Glucose Monitoring System.

ACON LABORATORIES,INC. B.04City, Country: San Diego, United States of America Email: [email protected] Website: www.acondiabetescare.com

ACON Diabetes Care, a part of ACON Laboratories, Inc., is headquartered in San Diego, California, USA. For over 10 years, ACON Diabetes Care has been focused on providing accurate, painless, and easy to use blood glucose monitoring systems and other related test systems to people with diabetes all over the world. Our products are sold in more than 130 countries world-wide and are highly recommended by health care professionals and clinical institutes.

43

EXHIBITOR PROFILESIndustry Exhibition

Adelphi Real World L.06City, Country: Bollington, United KingdomEmail: [email protected] Website: www.adelphigroup.com

20 year heritage conducting global Real World studies via Disease Specifi c Programmes & Bespoke Solutions using pub-lished methodology. Data in >50 disease areas (including dia-betes/range of CV conditions) collected from multiple stake-holders including physicians (PCP/specialist), patients (includ-ing validated PROs), carers and payers. Data used in c.400 publications in 40+ peer-reviewed journals and >100 scientifi c congresses to inform therapy guideline evolution and regulatory submissions.

Alere International Ltd M.07City, Country: Galway, Ireland Email: [email protected] Website: www.alere.com

About Alere Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometa-bolic disease and toxicology. For more information on Alere, please visit www.alere.com.

Allpresan – neubourg skin care V.03City, Country: Greven, Germany Email: [email protected] Website: www.allpresan.de

neubourg skin care (nsc) is a family business and brought the fi rst foot foam cream to the skin care market in the late 90s. From the very fi rst moment health care professionals and end consumers were fascinated by the outstanding characteristics of this product and its patented BarrioExpert® Technology: high effi cacy, fast penetration without greasy residues, breathability and twice the normal coverage compared to normal creams and ointments were convincing across the board.

44

EXHIBITOR PROFILES

Industry Exhibition

ARKRAY Europe B.V. D.11City, Country: Amstelveen, The Netherlands Email: [email protected] Website: www.arkray.eu

ARKRAY is the Japanese pioneer in self monitoring glucose de-vices and in diabetes care and diagnostics. Our high quality dia-betes testing and urinalysis Point of Care and Laboratory instru-ments have been appreciated for the last 40 years. Our latest HbA1c analyzer and Hospital Point of Care BGM will be available soon. Having offi ces almost all over the world and exporting to more than 80 countries, Arkray contributes to the health and well-being of people all the world.

ARTSANA S.P.A. - PIC SOLUTION L.01City, Country: Grandate, Italy Email: [email protected] Website: WWW.PICSOLUTION.COM

Pic Solution is a trademark of Artsana, leading Italian company in healthcare and baby products. Its new diabetes portfolio includes the wide Insupen Extr3me pen needles range featuring a special extra comfort needle geometry, High Flow TW 33Gx4mm and 32Gx4mm pen needles and the ReVita/ReDerma intensive treat-ment footcare range (sanitizer, lotion and cream plus anti-fl aking socks). Insumed syringes, Digitest lancing devices and lancets plus patient’s accessories complete the assortment.

Ascensia Diabetes Care N.03City, Country: Basel, Switzerland Email: [email protected] Website: www.ascensia.com

Ascensia Diabetes Care is a global specialist diabetes care company. Our mission is to empower people living with diabetes through innovative solutions that simplify and improve their lives. Home to the world renowned CONTOUR™ portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes manage their condition. Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd.

45


AstraZeneca N.01City, Country: Cambridge, United Kingdom Website: www.astrazeneca.com

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and com-mercialisation of prescription medicines, primarily for the treat-ment of cardiovascular, metabolic, respiratory, infl ammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Becton Dickinson France S.A.S. E.03City, Country: Le Pont de Claix, France Email: [email protected] Website: www.bd.com.

BD is a global medical technology company that is Advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solu-tions that help support the management of diabetes

bio.logis Center for Human Genetics L.05City, Country: Frankfurt am Main, Germany Email: [email protected] Website: www.biologis.com

bio.logis Center for Human Genetics (CfH) is a clinical institution with board certifi ed physicians for humangenetics. The complete spectrum of genetic diagnostics and counselling is offered for healthy clients, patients and physicians. Based on its expertise in human genetics the Center is also involved in the development of innovative IT-systems for genetic information management (GIM). GIM-IT allows all stakeholders in the healthcare system the translation of genetic info.

46

EXHIBITOR PROFILES

Industry Exhibition

Boehringer Ingelheim E.02City, Country: Ingelheim, GermanyEmail: [email protected]: www.boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affi liates and more than 47,500 employees. Metabolism is one area of focus for Boehringer Ingelheim’s research/development activities, with Diabetes an in-dication of central interest within the company’s global research network. Boehringer Ingelheim is committed to researching and developing new options to help those who live with Diabetes.

Cadila Healthcare Ltd. S.01City, Country: Ahmedabad, IndiaEmail: [email protected] Website: www.zyduscadila.com

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the fi eld of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharma-ceutical ingredients and animal healthcare products to wellness products. Recently, the group launched Exemptia, the world’s fi rst biosimilar for Adalimumab, the largest selling therapy world-wide for infl ammatory arthritis.

Cardiff University L.03City, Country: Cardiff, United KingdomEmail: [email protected] Website: www.diabetesdiploma.cf.ac.uk

Established in 2007 the Cardiff University Postgraduate Diabe-tes Diploma is the longest standing UK qualifi cation of its kind. With the latest additions of individual modules, the exclusive MSc Diabetes, Clinical Attachment schemes and bespoke work-shops, PGDE will have something to suit your needs. All of our programmes are distance learning offering the highest quality teaching to fi t around your current commitments. For more in-formation on any of our courses email [email protected]

47


Cellnovo Group A.02City, Country: Paris, FranceEmail: [email protected]: www.cellnovo.com

Cellnovo’s system is the world’s fi rst mobile diabetes manage-ment system comprised of a symphony of connected products – an insulin micro pump, activity monitor, cellular enabled wire-less touchscreen handset with integrated blood glucose meter and automatic connectivity to the secured server. The pump allows optimal management of insulin whilst ensuring extensive freedom of movement for patients. Real time patient data allows continual monitoring by family and healthcare professionals.

ClinTriCare GmbH & Co. KG G.01City, Country: Altenstadt, Germany Email: [email protected] Website: www.clintricare.com

Insourced Project Management for your Clinical Trial.

CODHy Q.05City, Country: Tel Aviv, Israel Email: [email protected] Website: www.codhy.com/la/2017/

Over the years, the Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) has built its name as a leading Clinical gathering that pertains to the Pros and Cons of important debates in the fi elds of Diabetes, Obesity and Hype tension, highlighting the interconnectivity of these fi elds. CODHy has become a central meeting ground for experts from around the world to share information central issues and debatable topics.

Crown Bioscience Inc. B.01City, Country: Santa Clara, United States of AmericaEmail: [email protected]: www.crownbio.com

Crown Bioscience, a global drug discovery and development so-lution company provides the most clinically translatable animal model in diabetes research, including the world’s largest collec-tion of spontaneously diabetic NHPs, unique polygenic rodent models, as well as conventional models of cardiovascular and metabolic disease. Our models and cutting edge technologies give clients maximum confi dence in preclinical results, reducing the risk and increasing the chance of success in the clinic.

48

EXHIBITOR PROFILES

Industry Exhibition

Danish Diabetes Academy Q.04City, Country: Odense, Denmark Email: [email protected] Website: www.danishdiabetesacademy.dk

The Danish Diabetes Academy is fi nanced by the Novo Nordisk Foundation and co-fi nanced by major universities and hospitals in Denmark. The Academy supports more than 130 researchers and organizes courses, seminars, workshops and conferences in cooperation with its stakeholders. It also organizes a PhD summer school and a Post Doc winter school. The events are open for international participants. The Academy seeks interna-tional partners for collaboration and further development of our services.

Dexcom, Inc. S.06City, Country: San Diego, United States of America Email: [email protected] Website: www.dexcom.com

Dexcom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by providing excep-tional continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. Our fl agship product, the Dexcom G5™ Mobile CGM System, is the fi rst FDA-approved, fully mobile CGM platform.

Diagnoptics Technologies B.V. U.05City, Country: Groningen, The NetherlandsEmail: [email protected] Website: www.diagnoptics.com

Diagnoptics develops and markets a non-invasive diagnostic technology, which can assess the tissue accumulation of AGEs: the AGE Reader. The AGE Reader enables a doctor to non-invasively assess the cardiovascular risk of their (diabetes) patients within 12 seconds. The extensively clinically validated AGE Reader is the new standard in point-of-care cardiovascular risk assess-ment. Diagnoptics now introduces a new concept of a compre-hensive cardiovascular risk assessment in 1 mobile app.

49


Diamesco Co., Ltd. S.02City, Country: Seoul, Republic of Korea Email: [email protected] Website: www.diamesco.com

Diamesco is committed to provide a better life for people with diabetes. Since our foundation, we have been doing our best to acquire global competitiveness. As an evidence of our effort, Diamesco has developed and commercialized digital insulin pen, digital insulin pump, patch-type insulin pump and CGMS (con-tinuous glucose monitoring system). We are pleased to intro-duce our products in EASD 2016 and looking forward to meeting you. Thank you very much.

Diasend AB B.03City, Country: Askim, Sweden Email: [email protected] Website: www.diasend.com

Edge Consulting srl B.02City, Country: Milan, ItalyEmail: [email protected]: www.edgeconsulting.it

Edge Consulting is a marketing research agency specialized in the pharmaceutical and healthcare area. We perform market researches both at Italian and International level, involving all fi gures playing a role in the market(KOLs,physicians, pharma-cists, patients,...).

EFPIA F.04City, Country: Brussels, Belgium Email: [email protected] Website: www.efpia.eu

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical com-panies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

50

EXHIBITOR PROFILES

Industry Exhibition

Eli Lilly and Company D.02City, Country: Indianapolis, United States of America Email: [email protected]: www.lillydiabetes.com

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s fi rst commercial insulin. Today, we con-tinue to build upon that heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions – from medicines to support programs and more – we strive to make life better for all those affected by diabetes.

Elsevier BV Q.06City, Country: Amsterdam, The NetherlandsWebsite: www.elsevier.com

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology pro-fessionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions and publishes over 3,800 journals and more than 35,000 book titles.

Emperra GmbH L.02City, Country: Potsdam, GermanyEmail: [email protected] Website: www.emperra.com

Established in 2008, Emperra GmbH E-Health Technologies is a research- and development-driven medical-technology company providing highly innovative approaches and solutions in the fi elds of e-health technologies and telediabetology. Emperra combines progressive software with future-oriented hardware, integrating these into a basic medical/scientifi c concept to provide tele-medicine product systems for patients with diabetes mellitus.

EOFLOW Co., Ltd. Q.02City, Country: Seongnam-Si, Republic of KoreaEmail: jesse@eofl ow.comWebsite: www.eofl ow.com

Eofl ow provides smart, disposable, wearable insulin pump solu-tion, EOPatch. This product is thinner, lighter, and lower cost than other solutions. It talks to third party sensors for improved diabetes management. It is just a software-upgrade away from being a fully closed loop solution.

51


Eyenuk Inc. B.02ACity, Country: Woodland Hills, United States of AmericaEmail: [email protected]: www.eyenuk.com Eyenuk presents EyeArt, its CE marked, fully-automated diabetic retinopathy screening solution that uses advanced image ana-lysis to enable diabetologists and internal medicine clinicians to perform imaging, grading, & reporting for diabetic retinopathy in a single offi ce visit, without needing expert human retinal image grading. It has been clinically validated on over 59,000 consecu-tive patient episodes from primary care centers demonstrating over 90% in both sensitivity and specifi city.

ForaCare Suisse AG M.03City, Country: St. Gallen, SwitzerlandEmail: [email protected]: www.foracare.ch

ForaCare Suisse AG is an established international supplier of innovative and secure healthcare products. We committed to improving the quality of life and providing accurate and prac-tical healthcare solutions in diabetes and hypertension care. By integrating each area with our advanced TeleHealth Solutions, healthcare professionals will be able to employ this information and make informed decisions when managing patients’ health conditions. At ForaCare, We bring care closer to patients.

Fukuda Denshi Co. Ltd P.01City, Country: Tokyo, Japan Email: [email protected]: www.fukuda.com

Fukuda Denshi (est. 1935), is a leading Japanese manufacturer of medical equipment and a market leader in cardiovascular screening in Japan. The VaSera VS-2000 offers a quick and easy way to measure arterial stiffness using ‘CAVI’ (Cardio-Ankle Vascular Index) and ABI (Ankle Brachial Index). The system assesses arterial stiffness, calculates the age of arteries, and checks for arterial blockages, independent of blood pressure, in under 5 minutes. Worldwide, 14,000 machines are in operation.

52

EXHIBITOR PROFILES

Industry Exhibition

gbo Medizintechnik AG Q.01City, Country: Rimbach, GermanyEmail: [email protected]: http://gbo-med.de/en-gbo-medizintechnik.html

gbo Medizintechnik AG is an established medium-sized company that sells and supports its products worldwide in over 70 countries. As a longtime partner for SIEMENS we have not only accumulated a solid know-how in medical engineering but have also developed a deep sense of quality.The HiToP® 191 has been designed to treat Polyneuropathy comfortably at home. gbo is exclusively applying the worldwide patented HighTone Therapy. Over 8.000 patients are using this therapy successfully.

GI Dynamics M.08City, Country: Düsseldorf, Germany Email: [email protected] Website: www.endobarrier.com

GI Dynamics is the developer of EndoBarrier®, the fi rst endo-scopically-delivered device therapy designed to mimic the mechanisms of metabolic surgery, without altering the anatomy. Through its EndoBarrier® Therapy, GI Dynamics is poised to ad-dress the growing diabetes and obesity patient populations.

GlaxoSmithKline G.03City, Country: London, United Kingdom Email: [email protected] Website: www.gsk.com

GSK it’s a global healthcare company on a mission We’re a science-led global healthcare company with a mission to help people do more, feel better, live longer. Our vaccines, consumer healthcare products and medicines touch the lives of millions of people. Today we are working to overcome some of the biggest healthcare challenges and create change to improve people’s lives.

53


Glenmark Pharmaceuticals Ltd S.01ACity, Country: Mumbai, India Email: [email protected] Website: www.glenmarkpharma.com

Glenmark Pharmaceuticals Ltd is a research driven, global, inte-grated pharmaceutical company. It is a leading player in the dis-covery of new molecules, both NCEs & NBEs with 7 molecules in various stages of clinical development & preclinical development Glenmark employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries & has 6 R&D centres.

HRA Healthcare Research & Analytics Q.03City, Country: Parsippany, United States of America Email: [email protected] Website: www.hraresearch.com

HRA gathers insights with actively engaged healthcare profes-sionals using self-administered surveys on ipads in the confi nes of our booth. We will be gathering answers to vital marketing and clinical questions - answers that can affect the introduction of new products or the continuation of existing healthcare pro-ducts and services. HRA provides solutions supporting decision-making/strategy development across healthcare channels.

IBL International GmbH F.05City, Country: Hamburg, Germany Email: [email protected] Website: www.tecan.com/immunoassays

IBL International – part of the Tecan Group – is an expert diag-nostics provider focusing on special and rare indications. The company offers a number of specialist diagnostic assays for Endocrinology, neurotransmitters, autoimmune disease and In-fectious disease in clinical diagnostics, along with key assays for the research segment, including assays for glucagon-like peptide-1 (GLP-1) which plays an essential role in the regulation of glucose homeostasis.

54

EXHIBITOR PROFILES

Industry Exhibition

IDx Europe B.V. V.02City, Country: Schiphol, The Netherlands Email: [email protected] Website: www.eyediagnosis.net

IDx (Iowa City, USA) was founded in 2011 by retinal and image-analysis experts who perceive the eye as a window to our health. IDx’s advanced algorithm-technology improves the quality, ac-cessibility and affordability of healthcare through the automation of medical diagnosis and treatment. The fi rst product from the IDx pipeline available for use in clinical practice in EU today is IDx-DR® (automated detection of diabetic retinopathy in retinal images).

iHealth Europe J.06City, Country: Paris, France Email: [email protected] Website: www.ihealthlabs.com

iHealth is a world leader in connected health, producing and dis-tributing innovative health products that allow users to better understand their bodies’ vital signs. iHealth has created a com-plete ecosystem of products, from blood pressure monitors, glucometers, body analysis scales and pulse oximeters, through to activity and sleep monitors. iHealth also offers a product line for health professionals, paired with a dedicated application called iHealthPro; connecting doctors and patients.

IME-DC GmbH J.10City, Country: Hof, Germany Email: [email protected] Website: www.imedc.de

The IME-DC Group is a worldwide company that is among the leading manufacturers of blood glucose meters and diabetes accessories. Our products are used not only in Germany, but in more than 30 countries throughout the world, for blood glucose testing and therapeutical support by medical pro-fessionals in hospitals, retirement and care homes, medical practices, pharmacies and for in-home care. In several European countries IME-DC operates as exclusive distribution partner for SOOIL Development.

55


Impeto Medical A.01City, Country: Paris, France Email: [email protected] Website: www.impeto-medical.com

Impeto Medical developed a patented technology assessing sudomotor function, which is linked to the status of small nerve fi bers innervating sweat glands. This type of nerve damage can be found early in diabetes & prediabetes. Based on this technology,Impeto Medical has developed: – SUDOSCAN for early detection & follow-up of Peripheral Autonomic Neuropathies – EZSCAN for early detection of Peripheral Autonomic Neuropathy as an alter-native method to screen for risk of diabetes or prediabetes

Infopia Co., Ltd. D.03City, Country: Kyunggi, Republic of Korea Email: [email protected] Website: www.infopia21.com/enNew/

Infopia, having developed biosensors for blood diagnosis since its establishment in 1996, is now exporting state-of-the-art bio-sensors for monitoring blood glucose and measuring HbA1c and cholesterol to about 100 countries around the world. We not only have the goal to be the best company in diagnostic bio distribution through developing sensors for diagnosing heart disease and cancers and remote diagnosing systems, etc., but also plan to drive business through maintaining human health.

Inside Biometrics Ltd F.06City, Country: Dingwall, Scotland Email: [email protected] Website: www.inside-biometrics.com

Inside Biometrics Ltd aims to bring innovative products to life that enhance the health and wellness of people with diabetes.The KEYA™ Smart blood glucose meter and KEYA™ test strips are manufactured by Inside Biometrics Ltd, a British company at the forefront of Biometric Health Tracking. KEYA™ Smart is a blood glucose meter with a difference. This innovative new technology has a unique 2-in-1 test strip designed to accurately measure both glucose and ketones simultaneously in just fi ve seconds

56

EXHIBITOR PROFILES

Industry Exhibition

Intarcia Therapeutics, Inc. R.03City, Country: Boston, United States of America Email: [email protected] Website: www.Intarcia.com

Intarcia Therapeutics, Inc. is developing innovative therapies that merge medicine and technology to transform the lives of patients suffering from chronic diseases. Our lead investigational compound, ITCA 650 (continuous subcutaneous delivery of exenatide), is currently being evaluated for type 2 diabetes in the FREEDOM Phase 3 clinical program. Our development pipe-line also includes other targets for metabolic and infl ammatory diseases.

Integrity Applications J.04City, Country: Ashdod, Israel Email: [email protected] Website: www.integrity-app.com

Integrity Applications (OTCQB: IGAP) has developed GlucoTrack®, an innovative, truly non-invasive glucose monitoring device for home use that allows diabetics to test their glucose levels with-out any needle and drawing blood. GlucoTrack utilizes a small sensor that is clipped to the ear lobe and connected to a hand-held companion control and display unit the the size of a smart-phone.Both visual and audible results are provided in about a minute. GlucoTrack model DF-F device has CE approved.

i-SENS, Inc. E.04City, Country: Seoul, Republic of Korea Email: [email protected] Website: www.i-sens.com

i-SENS, Inc. is a Korean biosensor technology company which is constantly improving the glucose monitoring process with dia-betes products. Currently, i-SENS exports to over 80 countries including the U.S., Europe, and Japan. Through its innovative product development program, i-SENS has developed Bluetooth and 3G enabled BGMS, dual function meter system for blood glucose and ketone testing, the world’s fi rst enzymatic HbA1c analyzer and diabetes management solutions.

57


INVITALIS GmbH Q.07City/Country: Ingolstadt, GermanyEmail: [email protected]: www.invitalis.com

INVITALIS – more than vitality

Janssen R.01City, Country: Beerse, Belgium Email: [email protected] Website: www.janssen-emea.com

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious disease and cardiovascular and meta-bolic diseases. Driven by our commitment to patients, we de-velop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partner-ships of trust and transparency.

Johnson & Johnson Family of Diabetes Care Companies R.01City, Country: Zug, Switzerland Email: [email protected] Website: www.jnj.com

The Johnson & Johnson Family of Diabetes Care Companies are a collaboration of Johnson & Johnson operating companies that are committed to advancing science that supports people with diabetes across the continuum of care. Participating in the EASD 2016 are: LifeScan, Inc., a world leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; Calibra Medical, Inc. developer of OneTouch Via™ on-demand insulin delivery; the Johnson & Johnson Dia-betes Institute, LLC, a global initiative to improve care and better outcomes worldwide through education and training programs; and Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, providing medicines for an array of health concerns in several therapeutic areas, including: diabetes, men-tal health, and cardiovascular disease.

58

EXHIBITOR PROFILES

Industry Exhibition

Karger Publishers G.02City, Country: Basel, Switzerland Email: [email protected] Website: www.karger.com

S. Karger Medical and Scientifi c Publishers is a leading inter-national publishing house of books and journals in basic and medical sciences. We offer a wide range of publications in endo-crinology including the book series ‘Frontiers of Diabetes. Visit our booth G.02 and browse through our latest publications: ‘Ad-vanced Therapies in Pediatric Endocrinology and Diabetology’, ‘Novelties in Diabetes’ and ‘Du & Ich haben Diabetes’.

LUPIN LTD U.02City, Country: Mumbai, India Email: corporateoffi [email protected] Website: www.lupin.com

Headquartered in Mumbai, Lupin is an innovation led trans-national pharmaceutical company. Lupin is a signifi cant player in the CVD, Diabetology, Asthma, Pediatric, CNS, GI, AI and NSAID and holds global leadership positions in the Anti-TB and Cepha-losporin segment. Lupin is the 5th largest generics player in the US (5.6% M.S by prescriptions, IMS Health) and amongst the fastest growing top 10 generic pharmaceutical players in Japan (ranked 9th) and South Africa (ranked 4th – IMS Health).

MED TRUST Handelsges.m.b.H. P.04City, Country: Marz, Austria Email: offi [email protected] Website: www.medtrust.at; www.wellion.at/en

MED TRUST is Austrian manufacturer and international specialist in the fi eld of diabetes and metabolism of humans and animals. With its own high-quality brands WELLION (human products) and WELLIONVET (veterinary products) we offer a comprehensive range of innovative products. We stand for continuity, reliability and sustainability. Our goal is to make life easier for patients and partners. Through innovative ideas, advice and service.

59


MEDEXEL CO. LTD A.03City, Country: Anseong, Republic of Korea Email: [email protected] Website: www.medexel.co.kr

MedExel, a Korean manufacturing company provides insulin pen needle since 2000. As company kept developing itself, MedExel recently launched the fi nest pen needle in the world, 34G! This 34G is recommended for people who are sensitive and have a fear in injection.The technology such as thin wall cannula, moderate silicone coatings and geometric cut of bevel shows the excellence of MedExel’s quality. For this reason MedExel is certifi ed by FDA, CE, CFDA and INVIMA, and exporting globally.

Medical Supply Co., Ltd. L.04City, Country: Wonju-si, South Korea Email: [email protected] Website: www.medicalsupply.co.kr

Recently in many countries, secondary infection through dis-posable sterile medical devices has become a matter of great concern. So, we have developed a brand-new lancet, “SafeLan” which can prevent needlestick injury and secondary infection by integrating needle, protective tip and cap. And, when it comes to our lancing device, it can prevent the transmitting blood-borne pathogens and minimize pain by accurate penetrating withour vibration of the needle.

Medscape Diabetes & Endocrinology S.05City, Country: New York, United States of America Email: [email protected] Website: medscape.com/diabetes-endocrinology

Medscape Diabetes & Endocrinology is the leading source of diabetes & endocrinology news and information for physicians and other healthcare professionals worldwide. We offer medical news, including practice guidelines, FDA announcements, jour-nal articles conference news, and thought leader perspectives; point-of-care clinical reference tools; and continuing medical edu-cation in a variety of engaging formats.

60

EXHIBITOR PROFILES

Industry Exhibition

Medtronic International Trading Sàrl E.01City, Country: Tolochenaz, Switzerland Email: [email protected] Website: medtronic.com

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our deep clinical, therapeutic and economic expertise to address the complex challenges faced by health-care systems today. Let’s take healthcare Further, Together. Learn more at Medtronic.com.

MEDTRUM TECHNOLOGIES INC. A.04City, Country: Shanghai, China Email: [email protected] Website: www.medtrum.com

Medtrum Technologies offers tubeless insulin pumps, continuous glucose monitoring systems, and a semi-closed loop system containing both pump and CGM. Our products are designed for both home and clinic use, bringing convenience to patients and healthcare providers. Our mission is to develop a closed-loop artifi cial pancreas to simplify diabetes management.

Mitsubishi Rayon Cleansui Co Ltd K.04City, Country: Tokyo, Japan Website: www.cleansui.co.uk

MSD J.02City, Country: Kenilworth, United States of America Email: [email protected] Website: www.msd.com

Today’s MSD is a global healthcare leader working to help the world be well. MSD is known as Merck in the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.

61


Mylan S.09City, Country: Allschwil, Switzerland Email: [email protected] Website: www.mylan.com

Mylan is one of the world’s leading global pharmaceutical com-panies with generic and branded products in a variety of dosage forms and therapeutic categories. The company has innovative R&D capabilities and is one of the world’s largest API manufac-turers. Mylan applies one global quality standard to all of our medications. Creating better health for a better world. That’s what inspires Mylan in our mission to provide quality healthcare to the world’s 7 billion people, one person at a time.

Novartis Pharma AG H.01City, Country: Basel, Switzerland Email: [email protected] Website: www.novartis.com

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversifi ed portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis products are available in more than 180 countries around the world. For more informa-tion, please visit http://www.novartis.com

novel gmbh G.07City, Country: Munich, Germany Email: [email protected] Website: www.novel.de

With more than 35 years of experience, novel is the leader in accurate and reliable load distribution measurement systems for pedographic analysis of the diabetic foot. Measuring the dynamic load distribution under the foot novel’s Pedography systems provide information about local pressure, foot structure and function, and give a baseline for the construction of appropriate shoes and orthotics. Prominent major clinics, universities and research institutions worldwide rely on novel´s technology.

62

EXHIBITOR PROFILES

Industry Exhibition

Novo Nordisk A/S H.02 / J.03City, Country: Bagsvaerd, Denmark Email: [email protected] Website: www.novonordisk.com

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products in more than 180 countries. For more information, visit novonordisk.com

Optomed Oy P.02City, Country: Oulu, Finland Email: [email protected] Website: www.optomed.com

Optomed Oy is a Finnish medical technology company that specializes in retinal imaging devices and solutions. The prod-uct portfolio consists of digital imaging instruments that pro-vide retinal and eye anterior imaging with one portable device. Key product is Smartscope® PRO, a modular hand-held retinal camera for screening and diagnosis of various eye diseases. Smartscope’s image quality fulfi lls international ISO 10940 fundus camera standard requirements.

Phoenix Europe GmbH Q.09City, Country: Karlsruhe, Germany Email: [email protected] Website: www.phoenixpeptide.eu

Phoenix Europe GmbH specializes in peptide assays for diabetes, obesity, cardiovascular and endocrine related hormones. Other products include diabetes / obesity related peptides and anti-bodies or the new non-radioactive, highly sensitive fl uorescent and chemiluminescent EIA assays. We also offer custom synthe-sis or labeling and hormone level determination. With over 40 obesity related peptides in publications today, Phoenix is always the leader in diabetes / obesity related peptide discoveries.

63


POCTech Medical M.04City, Country: Beijing, China Email: [email protected] Website: www.poctechcorp.com

POCTech Corp. is proud to showcase a new CT100 Continuous Glucose Monitoring (CGM) subcutaneous sensor product to the diabetes community. A clinical trial was completed in 2015, in-volving 80 patients in two hospitals. The overall MARD’s (vs fi nger sticks) of 9.61% and of 8.67% (vs venous blood glucose) were achieved. CE Mark Certifi cation has been granted. POCTech focuses on the development, manufacturing, data management and customer support of CGM products.

PODARTIS SRL G.07City, Country: Montebelluna, Italy Email: [email protected] Website: www.podartis.com

Podartis has more than 20 years of experience and study on the foot diseases and ten years of experience and stable growth in the market.Podartis has a complete range of products focused on the treatment of fragile feet of adults and on foot patholo-gies: diabetes, rheumatic diseases, post-surgery, rehabilitation, elderly people’s diseases and protected physical activity and it is the only company, in the orthotic sector, with each product clinically and biomechanically tested.

REGENERON D.04City, Country: Tarrytown, United States of America Email: [email protected] Website: www.regeneron.com

Regeneron is a leading science-based biopharma. company based in Tarrytown (NY)that discovers, invents, develops, manu-factures, and commercializes medicines for the treatment of se-rious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare infl ammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheu-matoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.

64

EXHIBITOR PROFILES

Industry Exhibition

Research Diets, Inc. U.01City, Country: New Brunswick, United States of America Email: [email protected] Website: www.ResearchDiets.com

Research Diets, Inc. formulates and produces purifi ed Open-Source® Diets for laboratory animals. Our Resource Center is staffed with scientists who consult with customers around the world on diet formulations. Custom diets shipped in 5-7 days. BioDAQ® Food and Liquid Intake Monitor for mice and rats mounts to home cage, records the time, duration, amount of each meal automatically. Automated gate is programmable by time or amount consumed. BioDAQ NHP monitors food intake of socially housed NHPs.

Roche Diabetes Care GmbH J.01City, Country: Mannheim, Germany Email: [email protected] Website: www.accu-chek.com

Roche Diabetes Care is a global market leader in personalized diabetes management. The company provides cutting-edge inno-vations since more than 40 years, helping people with diabetes and caregivers to optimally manage the condition – and expe-rience true relief from the daily diabetes routines. The portfolio comprises e.g. smart bG meters like the Accu-Chek® Guide inte-grating with the cloud-based Accu-Chek® Connect platform and latest sensor technology as with the Accu-Chek® Insight CGM system.

SANOFI D.04 / M.01City, Country: Paris, France Website: www.sanofi .com

Building on our portfolio evolution, heritage and expertise, Sanofi has a focused business unit dedicated to delivering innovative, value-based medicines and integrated solutions in Diabetes and Cardiovascular . We are committed to a collaborative approach with the goal of advancing scientifi c knowledge, driving the convergence of science and technology, helping to improve out-comes and inspiring an evolution in care.

65


SERVIER R.02City, Country: Suresnes, France Website: www.servier.com

Servier is the leading French independent pharmaceutical company with 21 000 employees in 148 countries. Servier’s commitment to innovative research underlines its mission to provide therapeutic innovation to healthcare professionals and improve patient care in diabetes, cardiovascular, neurologic and psychiatric diseases, and cancer. With Intarcia (USA and Japan), Servier is developing the fi rst injection-free GLP-1 RA that may change the management of type 2 diabetes.

Shenzhen Lifotronic Technology Co.,Ltd K.03City, Country: Shenzhen, ChinaEmail: [email protected]: en.lifotronic.com

Lifotronic is a medical company for In vitro diagnostic ana-lyzer having more than 360 staffs and 15000 m2 with turn over bigger than $35 Million. In 2016 we launched the cooperation with SYSMEX on full automated CRP analyzer (nephelometry) which is a big event in domestic IVD industry. Our main products are HPLC HbA1c Analyzer, Specifi c Protein Analyzer, Immunofl uo-rescence analyzer (POCT) for many parameters including HbA1c, PCT, CRP, HCG, NT-proBNP, D-dimer, mAlb, Cys-c, cTnI, CK-MB, Myo etc.

SOOIL Development Co., Ltd. M.06City, Country: Seoul, South Korea Email: [email protected] Website: www.sooil.com/new/eng/main.htm

SOOIL Development is committed to producing the innovative medical solutions for diabetes throughout the world. With our slogan “Deliver joy to the people with diabetes”, the company has a long and robust history for 37 years. SOOIL has been improving insulin pump system through clinical and research ap-plications from 1979 when the founder of SOOIL developed his fi rst portable insulin pump.

66

EXHIBITOR PROFILES

Industry Exhibition

Steno Diabetes Center U.04City, Country: Copenhagen, Denmark Email: [email protected] Website: steno.dk

Steno Diabetes Center presents new digital learning offerings to improve clinical diabetes care. At booth U.04 in Hall B1, participants can experience Steno Diabetes Center’s new on-line courses in clinical diabetes management and interact with the Steno Education App, which can be downloaded for free in App-store and Google play.

Takeda Pharmaceuticals International AG D.01City, Country: Zurich, Switzerland Email: [email protected] Website: www.takeda.com

For more than 230 years, Takeda has been committed to serving the global community through health care solutions from prevention, to care, to cure. Takeda has built a strong foundation in and maintained a robust focus on Type 2 diabetes for more than 20 years. Our diverse portfolio of available medications demonstrates Takeda’s commitment to advancing patient care and helping to meet the individual needs of this growing patient population.

The JAMA Network P.03City, Country: Chicago, United States of America Email: [email protected] Website: www.jamanetwork.com

Building on a tradition of editorial excellence, The JAMA Network brings JAMA together with 11 specialty journals to offer en-hanced access to the research, viewpoints, and medical news shaping medicine today and into the future. JAMA Cardiology, a new peer-reviewed journal, will launch in 2016.

Time Research Limited G.04City, Country: London, United KingdomEmail: [email protected] Website: www.timeresearch.co.uk

Time Research is a market research agency based in London, England. We warmly welcome EASD delegates to our booth and participate in our international study.

67


Trividia Health, Inc. S.07City, Country: Fort Lauderdale, United States of America Email: [email protected] Website: www.trividiahealth.com

Trividia Health, Inc. is the only manufacturer exclusively focused on helping people with diabetes maintain a healthy lifestyle. From meters and test strips, sharps, nutrition and skin care, each TRUE solution complements the next, forming one power-ful, interconnected system to help people with diabetes keep the body in balance.

VibroSense Dynamics AB F.03City, Country: Malmö, Sweden Email: [email protected] Website: www.vibrosense.com

VibroSense Dynamics develops and markets effi cient systems for early detection and diagnosis of peripheral sensory neuro-pathy in the legs and arms. VibroSense are currently developing a new medical device for assessment and early diagnosis of Diabetic Peripheral Neuropathy (DPN) of feet, based on the com-pany’s core technology Multi Frequency Vibrometry. The product portfolio includes a CE-marked device, the VibroSense Meter, for diagnosis of impaired sensitivity in the hands.

ViCentra BV V.01City, Country: Utrecht, The Netherlands Email: [email protected] Website: www.hellokaleido.com

Hello Munich! Last year we had a blast introducing you to Kaleido – pump therapy for those who don’t believe in boring. This year, we’re back with more! We’ve got a pump that’s as vibrant and individual as the people we’ve designed it for, we’re not afraid of putting diabetes back in its place and showing it who’s boss, we’re CE marked – and we’re raring to go! Sound good to you? Great – let’s do this! Head on over to our stand and say hello. We’re ready to inject some colour – are you!?

68

EXHIBITOR PROFILES

Industry Exhibition

VPD BLED d.o.o. G.05City, Country: Bled, Slovenia Email: [email protected] Website: www.2in1.si

2in1 is VPD’s worldwide recognized brand for self control Blood Glucose level. Systems are available with SW applications integrated in smart phones using iOS and Android operating systems. The portfolio of products contains different models of BGM for all generations.

Welch Allyn K.05City, Country: Leiden, The NetherlandsEmail: [email protected]: www.welchallyn.com

Since 1915 Welch Allyn has brought a unique perspective to developing diagnostic solutions by combining pragmatic know-ledge with a visionary spirit of innovation. As a leading global manufacturer of physical examination instruments, screening devices and EMR-connected vital signs solutions, the company has a steadfast commitment to delivering superlative medical products and services that help healthcare professionals provide better care for their patients. Now part of the Hill-Rom family.

Wiley G.06City, Country: Oxford, United Kingdom Email: [email protected] Website: www.onlinelibrary.wiley.com/

Wiley’s Global Research business is a provider of content-enabled solutions to improve outcomes in research, education and pro-fessional practice with online tools, journals, books, databases, reference works and laboratory protocols. Through Wiley Online Library, we provide online access to a broad range of content: over 4 million articles from 1,500 journals, 9,000+ books, and many reference works and databases.

69


Wisepress Medical Bookshop P.05City, Country: London, United Kingdom Email: [email protected] Website: www.wisepress.com

Wisepress.com, Europe’s leading conference bookseller, has a range of books and journals relevant to the themes of the meeting. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientifi c book-shop online with great offers. Follow us on Twitter for the latest news @WisepressBooks.

Wuxi Apex Medical Co., Ltd. L.07City, Country: Wuxi, China Email: [email protected] Website: www.apexdiabetes.com

Apex Medical, established in 2006 is focused on providing customers solutions for medication infusion. Our products include insulin pump, infusion pump, various kinds of subcutaneous in-fusion set and syringe. Apex Medical started international busi-ness in 2011 after we get CE approved. Now our products are widely used in Russia, Denmark, Greece, Italy, Austria, Malaysia, Argentina etc.

Ypsomed AG N.02City, Country: Burgdorf, Switzerland Email: [email protected] Website: www.ypsomed.com

More freedom. More confi dence. With mylife™. mylife™ is a range of products and services for people with diabetes. It pro-vides everything they need for simple and reliable self-medication: from blood glucose monitoring systems to pen needles and infu-sion systems, all in a modern, functional and aesthetically pleasing design. The company behind mylife™ is Ypsomed, a Swiss-based global leader in the fi eld of medical technology. mylife™ Diabetes-care − Ypsomed’s brand for people with diabetes.

70

EXHIBITOR PROFILES

Industry Exhibition

71

HEAD

71

HEAD

71

IMPRINT

c/o INTERPLAN AGLandsberger Strasse 15580687 MunichGermany

Phone: +49 (0) 89 54 82 34-67Fax: +49 (0) 89 54 82 34-45Email: [email protected]: www.interplan.de

Each company is responsible for the content of their symposium.Status: August 2016. All subjects to change.

INTERPLANmedia & service gmbh

INDUSTRY PROGRAMME2016.easd-industry.com/files/EASD16/EASD16_Ind... · FLASH GLUCOSE MONITORING:...

Documents

Transcript of INDUSTRY PROGRAMME2016.easd-industry.com/files/EASD16/EASD16_Ind... · FLASH GLUCOSE MONITORING:...